Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer

B. E. P. J. Vriens, M. J. B. Aarts, B. de Vries, S. M. van Gastel, J. Wals, T. J. Smilde, L. J. C. van Warmerdam, M. de Boer, D. J. van Spronsen, G. F. Borm, V. C. G. Tjan-Heijnen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)3102-3110
JournalEuropean Journal of Cancer
Issue number15
Publication statusPublished - Oct 2013


  • Breast cancer
  • Cyclophosphamide
  • Docetaxel
  • Doxorubicin
  • Neoadjuvant chemotherapy

Cite this